Immunotherapy plus chemo and SBRT before surgery for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have limited-stage small cell lung cancer that has not spread far, and your doctors believe it can be removed with surgery.
- You have not had any previous treatment for your lung cancer (like surgery, chemo, or radiation).
- Your overall health is good (ECOG score 0-1, meaning you can take care of yourself and are up and about more than half the day).
- Your heart and lungs are strong enough for surgery, with specific tests showing adequate function.
- You agree to use effective birth control if you are able to have children, from the start of the study until 180 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This Phase 3 trial tests whether adding a drug called adebrelimab (SHR-1316) to standard chemotherapy before treatment leads to more successful surgery and/or radiation for limited-stage small cell lung cancer. It’s for people who have not had any prior cancer treatment and can undergo planned “curative” treatment after 4 cycles.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Hear when a new Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.